Lara Krupka-Longpre
Corporate Officer/Principal at MIRUM PHARMACEUTICALS, INC.
Net worth: 3 M $ as of 31/05/2024
Network origin in Lara Krupka-Longpre first degree
Entity | Entity type | Industry | |
---|---|---|---|
Public Company | Pharmaceuticals: Major | 27 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Lara Krupka-Longpre via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Pharmaceuticals: Major | General Counsel Chief Operating Officer Corporate Officer/Principal Director/Board Member | |
Frazier Management LLC
Frazier Management LLC Investment ManagersFinance Frazier Management LLC (Frazier Healthcare Partners) is a venture capital subsidiary of Frazier & Co Inc. founded in 1991. The firm is headquartered in Seattle, Washington. | Investment Managers | Private Equity Investor Consultant / Advisor | |
BIOMARIN PHARMACEUTICAL INC. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer | |
INTERMUNE INC | Biotechnology | Director/Board Member Corporate Officer/Principal | |
HTG MOLECULAR DIAGNOSTICS, INC. | Miscellaneous Commercial Services | Director/Board Member | |
ANAPTYSBIO, INC. | Biotechnology | Director/Board Member | |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal Director/Board Member | |
SillaJen Biotherapeutics, Inc.
SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Miscellaneous Commercial Services | Chief Executive Officer Corporate Officer/Principal | |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Corporate Officer/Principal Masters Business Admin | |
University of California, Berkeley | College/University | Undergraduate Degree Undergraduate Degree | |
The University of California, San Francisco | College/University | Doctorate Degree Corporate Officer/Principal | |
Norwest Venture Partners
Norwest Venture Partners Investment ManagersFinance Norwest Venture Partners is a venture capital division of Norwest Partners founded in 1961. The firm is headquartered in Palo Alto, California with additional offices in Mumbai and Herzliya. | Investment Managers | Private Equity Investor | |
University of Geneva | College/University | Doctorate Degree Doctorate Degree | |
NEVRO CORP. | Medical Specialties | Director/Board Member | |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Director/Board Member | |
OTONOMY | Biotechnology | Director/Board Member | |
RAPTOR PHARMACEUTICAL CORP | Pharmaceuticals: Major | Director/Board Member Compliance Officer | |
ALLERGAN PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Ziarco Pharma Ltd.
Ziarco Pharma Ltd. BiotechnologyHealth Technology Ziarco Pharma Ltd. provides therapeutics targeting inflammatory and allergic diseases. It focuses on chronic inflammatory skin diseases, atopic dermatitis, and Psoriasis. The company was founded by Michael Yeadon, Wai Leung Liu, Lynn Worth Purkins and Arif Kassam Shivji in 2012 and is headquartered in Sandwich, the United Kingdom. | Biotechnology | Chairman Chairman | |
Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
Stanford Graduate School of Business | College/University | Masters Business Admin Masters Business Admin | |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Biotechnology | Director/Board Member | |
MDLIVE, Inc.
MDLIVE, Inc. Packaged SoftwareTechnology Services MDLIVE, Inc. operates as a telehealth provider of online and on-demand healthcare delivery services and software. Its cloud-based virtual medical office software platform enables patients, medical professionals, and plan administrators to collaborate through voice, video, email, and mobile devices; and allows payers and providers to collect and share clinical data from patient medical records, lab results, and in-home biometric devices for real-time risk assessments, wellness advice, diagnosis, and treatment. The company was founded by Randy Parker and Steven Victor Gurland in 2009 and is headquartered in Sunrise, FL. | Packaged Software | Director/Board Member | |
Ziarco Group Ltd.
Ziarco Group Ltd. Pharmaceuticals: MajorHealth Technology Ziarco Group Ltd. operates as a clinical-stage biotechnology company that develops therapeutics targeting inflammatory skin diseases. The firm engages in development of novel treatments in dermatology. The company was incorporated on March 10, 2014 and is headquartered in Canterbury, the United Kingdom. | Pharmaceuticals: Major | Chairman Chairman Director/Board Member | |
RENEO PHARMACEUTICALS, INC. | Biotechnology | Founder Director/Board Member Founder Director/Board Member | |
TOBIRA THERAPEUTICS INC | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Investor Relations Contact Director/Board Member Chief Tech/Sci/R&D Officer Director of Finance/CFO | |
Senti Sub I, Inc.
Senti Sub I, Inc. BiotechnologyHealth Technology Senti Biosciences, Inc. develops novel therapeutics. It specializes in thetic biology, gene therapy and cell therapy. The company was founded by Timothy K. Lu, Wilson Wong, James J. Collins and Philip Lee in 2016 and is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member Director/Board Member | |
SPRUCE BIOSCIENCES, INC. | Biotechnology | Chairman Director/Board Member Director/Board Member | |
AKOUOS | Biotechnology | Director/Board Member Director/Board Member | |
SpliceBio SL
SpliceBio SL BiotechnologyHealth Technology SpliceBio SL is a genetic medicines company based in Barcelona, Spain. The Spanish company harnesses its proprietary protein splicing platform to develop the next generation of gene therapies. SpliceBio's platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by -associated virus (AAV) vectors. The company's lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio's platform is based on technology developed in the Muir lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. The company was founded by Dominguez Silvia Frutos, Miquel Vila-Perelló, and Miquel Vila-Perelló has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
Flashlight Therapeutics, Inc.
Flashlight Therapeutics, Inc. BiotechnologyHealth Technology Flashlight Therapeutics, Inc. develops therapeutics for unmet medical needs. | Biotechnology | Chief Tech/Sci/R&D Officer Chief Executive Officer | |
MBX Biosciences, Inc.
MBX Biosciences, Inc. Electronic Equipment/InstrumentsElectronic Technology MBX Biosciences, Inc. operates as a preclinical-stage biotech company. It creates therapies to treat rare endocrine diseases. The company was founded by Peter Kent Hawryluk and Timothy Knickerbocker and is headquartered in Carmel, IN. | Electronic Equipment/Instruments | Director/Board Member Director/Board Member Director/Board Member | |
Curzion Pharmaceuticals, Inc.
Curzion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Curzion Pharmaceuticals, Inc. operates as a pharmaceutical firm. The company is headquartered in San Diego, CA. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Founder | |
Allievex Corp.
Allievex Corp. Pharmaceuticals: OtherHealth Technology Allievex Corp. operates as a biotechnology company. It develops therapies for the treatment of rare pediatric neurodegenerative diseases. The company was founded by Thomas P. Mathers and Eric H. Zanelli and is headquartered in Marblehead, MA. | Pharmaceuticals: Other | Director/Board Member | |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Biotechnology | Director/Board Member | |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
SENTI BIOSCIENCES, INC. | Biotechnology | Director/Board Member | |
Sorriso Pharmaceuticals, Inc.
Sorriso Pharmaceuticals, Inc. BiotechnologyHealth Technology Sorriso Pharmaceuticals, Inc. is an American biotechnology company that focuses on developing disease-modifying antibodies to treat inflammatory diseases. Sorriso Pharmaceuticals was founded by Ciara Kennedy, who has been the CEO since its incorporation. | Biotechnology | Chairman Director/Board Member | |
Ray Therapeutics, Inc.
Ray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Ray Therapeutics, Inc. is an American company that is developing a lead candidate, RTX-015, to treat retinitis pigmentosa, a degenerative retinal disease. Ray Therapeutics is based in an undisclosed location. The company's mission is to restore vision for people with retinal degeneration using optogenetics gene therapies. Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company was founded by Paul Bresge and Sean Ainsworth, with Paul Bresge serving as CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member | |
Rezo Therapeutics, Inc.
Rezo Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Rezo Therapeutics, Inc. is a drug discovery company based in San Francisco, CA. The company's mission is to revolutionize traditional drug development by integrating proteomics, genetics, structural biology, chemistry, artificial intelligence, and machine learning to create maps of molecular disease networks. Rezo's initial focus is on oncology, but they plan to explore additional therapeutic areas through collaborations and partnerships. The company was founded by Natalia Jura, Kevan Shokat, Nevan Krogan, Sourav Bandyopadhyay, Norbert W. Bischofberger, and George A. Scangos, with Nevan Krogan serving as CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member |
Statistics
International
United States | 45 |
Ireland | 3 |
United Kingdom | 3 |
Switzerland | 2 |
Spain | 2 |
Sectoral
Health Technology | 36 |
Consumer Services | 7 |
Commercial Services | 6 |
Finance | 3 |
Technology Services | 2 |
Operational
Director/Board Member | 269 |
Independent Dir/Board Member | 99 |
Corporate Officer/Principal | 70 |
President | 28 |
Chairman | 26 |
Most connected contacts
Insiders | |
---|---|
Ed Mathers Mathers | 47 |
Jonathan Leff | 45 |
Patrick Heron | 42 |
Timothy Walbert | 40 |
Michael Grey | 32 |
Laura Brege | 27 |
Carol Brosgart | 25 |
Tiba Aynechi | 24 |
Laurent Fischer | 23 |
Eric Bjerkholt | 21 |
Sona Saira Ramasastry | 19 |
Niall O'Donnell | 17 |
William Fairey | 15 |
Lon Cardon | 13 |
Joanne Quan | 12 |
- Stock Market
- Insiders
- Lara Krupka-Longpre
- Company connections